<DOC>
	<DOCNO>NCT02152124</DOCNO>
	<brief_summary>Acromegaly rare hormonal disorder lead increased morbidity mortality . In vast majority case , pituitary somatotroph cell adenoma cause excess growth hormone ( GH ) secretion , lead hepatic insulin-like-growth factor 1 ( IGF-1 ) hypersecretion . Both disease well treatment long-acting somatostatin analog ( LA-SMSA ) and/or pegvisomant affect glucose lipid metabolism , possibly contribute increase cardiovascular risk . In pilot study , investigator want explore insulin sensitivity , postprandial gut hormone response , lipid handle adipocytokine profile follow 4 group : - control acromegalic patient LA-SMSA ( group 1 ) - control acromegalic patient combination treatment LA-SMSA pegvisomant ( group 2 ) - acromegalic patient without need medical therapy surgery ( group 3 ) - healthy control subject ( group 4 ) Furthermore , longitudinal exploration perform uncontrolled acromegalic patient ( i.e . patient serum IGF-1 level age-specific threshold and/or symptom due active acromegaly ( excessive sweating , arthralgia ) ) LA-SMSA monotherapy ( group 5 ) . In group , insulin sensitivity , postprandial gut hormone response , lipid handle adipocytokine profile explore introduce pegvisomant three month normalisation IGF-1 level . The investigator hypothesize lipid glucose handle less efficient control acromegalic patient LA-SMSA controlled patient combination therapy surgery , difference substrate metabolism healthy control control acromegalic patient combination treatment surgery . Further , hypothesize introduce pegvisomant uncontrolled acromegalic patient improve postprandial lipid glucose handling .</brief_summary>
	<brief_title>Growth Hormone , IGF-1 Medical Treatment Acromegaly : Are There Effects Gut Hormone Physiology Postprandial Substrate Metabolism ?</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Diagnosis acromegaly 1 year ago , change treatment schedule since least 6 month ( group 13 5 ) OR healthy volunteer without diagnosis acromegaly ( group 4 ) Patient willing participate sign informed consent Age &gt; 18 year &lt; 80 year Body Mass Index 1840 kg/mÂ² Biochemistry : liver function test &gt; 3x ULN ; HbA1C &gt; 58 mmol/mol All untreated endocrine disorder include uncontrolled diabetes mellitus type 2 ( i.e . HbA1C &gt; 58 mmol/mol ) Bariatric surgery ; malabsorptive syndrome ; hepatic renal failure Current medication use : insulin , metformin , sulfonylurea , fibrates , incretin mimetics , dopamine agonist ( insulin , participation allow 2 week washout period ) Abuse alcohol drug Weight change &gt; 10 % body weight precede 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Acromegaly</keyword>
	<keyword>Acromegaly treatment</keyword>
	<keyword>Long-acting somatostatin analog</keyword>
	<keyword>Pegvisomant</keyword>
	<keyword>Insulin sensitivity</keyword>
	<keyword>Gut hormone</keyword>
	<keyword>Lipid metabolism</keyword>
	<keyword>Adipokines</keyword>
</DOC>